Motility Enhancement by Tumor-Derived Mutant E-Cadherin Is Sensitive to Treatment with Epidermal Growth Factor Receptor and Phosphatidylinositol 3-Kinase Inhibitors

2002 ◽  
Vol 276 (2) ◽  
pp. 129-141 ◽  
Author(s):  
Margit Fuchs ◽  
Peter Hutzler ◽  
Ingrid Brunner ◽  
Jürgen Schlegel ◽  
Jörg Mages ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Phosphatidylinositol 3 Kinase ◽  
Epidermal Growth ◽  
Phosphatidylinositol 3 ◽  
E Cadherin

Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study

2007 ◽  
Vol 25 (17) ◽  
pp. 2406-2413 ◽  
Author(s):  
Linda L. Garland ◽  
Cathryn Rankin ◽  
David R. Gandara ◽  
Saul E. Rivkin ◽  
Katherine M. Scott ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Survival Time ◽  
Growth Factor Receptor ◽  
Pleural Mesothelioma ◽  
Phosphatidylinositol 3 Kinase ◽  
Epidermal Growth ◽  
Egfr Tki ◽  
Phosphatidylinositol 3

Purpose Malignant pleural mesothelioma (MPM) expresses high levels of epidermal growth factor receptor (EGFR), and preclinical studies have identified antitumor activity of EGFR tyrosine kinase inhibitors (TKIs) in MPM. We conducted a phase II trial of the EGFR TKI erlotinib in previously untreated patients with MPM. Patients and Methods Patients with measurable and nonmeasurable disease were treated with erlotinib 150 mg/d on days 1 through 28 of each 28-day dosing cycle. Archived patient tumors were analyzed for immunohistochemical expression of EGFR, phospho-EGFR, human epidermal growth factor receptor 2 (HER2), phospho–extracellular signal-regulated kinase (ERK), and phosphatase and tensin homolog (PTEN) and phosphorylation of members of the phosphatidylinositol 3-kinase/Akt signaling pathway. Results Sixty-three patients were treated on the study. EGFR was highly expressed in 75% of patient tumors, as was phospho-ERK (82%), phospho-Akt (84%), phospho–mammalian target of rapamycin (74%), and phospho-forkhead (74%). HER2 was rarely expressed, and loss of PTEN was rare. For 33 patients with measurable disease, there were no objective responses; 14 patients (42%) had stable disease, 15 patients (45%) had disease progression, and four patients had inadequate assessments to determine response. Toxicities were mainly constitutional (51%), dermatologic (82%), and GI (52%); there was one death on trial, which was related to dyspnea. Median overall survival time was 10 months; 1-year survival rate was 43%; and median progression-free survival time was 2 months. Conclusion Single-agent erlotinib was not effective in MPM, despite high expression of EGFR. Activation of the ERK and phosphatidylinositol 3-kinase/Akt downstream pathways are possible resistance mechanisms to EGFR TKI. The activated phosphatidylinositol 3-kinase/Akt pathway is a potential therapeutic target for MPM.

Sign in / Sign up

Export Citation Format

Share Document